Literature DB >> 30567480

Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report.

Feiming Ye1,2, Ya Wang1,2, Congqing Wu2, Deborah A Howatt2, Chia-Hua Wu3, Anju Balakrishnan2, Adam E Mullick4, Mark J Graham4, A H Jan Danser5, Jian'an Wang1, Alan Daugherty2,3,6, Hong S Lu2,3,6.   

Abstract

Objective- AGT (Angiotensinogen) is the unique precursor of the renin-angiotensin system that is sequentially cleaved by renin and ACE (angiotensin-converting enzyme) to produce Ang II (angiotensin II). In this study, we determined how these renin-angiotensin components interact with megalin in kidney to promote atherosclerosis. Approach and Results- AGT, renin, ACE, and megalin were present in the renal proximal convoluted tubules of wild-type mice. Hepatocyte-specific AGT deficiency abolished AGT protein accumulation in proximal tubules and diminished Ang II concentrations in kidney, while renin was increased. Megalin was most abundant in kidney and exclusively present on the apical side of proximal tubules. Inhibition of megalin by antisense oligonucleotides (ASOs) led to ablation of AGT and renin proteins in proximal tubules, while leading to striking increases of urine AGT and renin concentrations, and 70% reduction of renal Ang II concentrations. However, plasma Ang II concentrations were unaffected. To determine whether AGT and megalin interaction contributes to atherosclerosis, we used both male and female low-density lipoprotein receptor-/- mice fed a saturated fat-enriched diet and administered vehicles (PBS or control ASO) or megalin ASO. Inhibition of megalin did not affect plasma cholesterol concentrations, but profoundly reduced atherosclerotic lesion size in both male and female mice. Conclusions- These results reveal a regulatory role of megalin in the intrarenal renin-angiotensin homeostasis and atherogenesis, positing renal Ang II to be an important contributor to atherosclerosis that is mediated through AGT and megalin interactions.

Entities:  

Keywords:  angiotensinogen; angiotensins; atherosclerosis; mice; renin

Mesh:

Substances:

Year:  2019        PMID: 30567480      PMCID: PMC6344256          DOI: 10.1161/ATVBAHA.118.311817

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  51 in total

1.  On the Origin of Urinary Renin: A Translational Approach.

Authors:  Lodi C W Roksnoer; Bart F J Heijnen; Daisuke Nakano; Janos Peti-Peterdi; Stephen B Walsh; Ingrid M Garrelds; Jeanette M G van Gool; Robert Zietse; Harry A J Struijker-Boudier; Ewout J Hoorn; A H Jan Danser
Journal:  Hypertension       Date:  2016-02-29       Impact factor: 10.190

2.  Relation between renin substrate and acute phase proteins. Studies of normal and adrenalectomized rats.

Authors:  J Bing
Journal:  Acta Pathol Microbiol Scand A       Date:  1972

3.  Multiphoton imaging of the glomerular permeability of angiotensinogen.

Authors:  Daisuke Nakano; Hiroyuki Kobori; James L Burford; Haykanush Gevorgyan; Saskia Seidel; Hirofumi Hitomi; Akira Nishiyama; Janos Peti-Peterdi
Journal:  J Am Soc Nephrol       Date:  2012-09-20       Impact factor: 10.121

4.  Angiotensinogen Exerts Effects Independent of Angiotensin II.

Authors:  Hong Lu; Congqing Wu; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Xiaofeng Chen; Mingming Zhao; Mark J Graham; Adam E Mullick; Rosanne M Crooke; David L Feldman; Lisa A Cassis; Craig W Vander Kooi; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

5.  Liver angiotensinogen is the primary source of renal angiotensin II.

Authors:  Taiji Matsusaka; Fumio Niimura; Akihiro Shimizu; Ira Pastan; Akihiko Saito; Hiroyuki Kobori; Akira Nishiyama; Iekuni Ichikawa
Journal:  J Am Soc Nephrol       Date:  2012-04-19       Impact factor: 10.121

6.  Immunostaining of mouse atherosclerotic lesions.

Authors:  Hong Lu; Debra L Rateri; Alan Daugherty
Journal:  Methods Mol Med       Date:  2007

Review 7.  Translating molecular discoveries into new therapies for atherosclerosis.

Authors:  Daniel J Rader; Alan Daugherty
Journal:  Nature       Date:  2008-02-21       Impact factor: 49.962

8.  Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice.

Authors:  Daiju Fukuda; Masataka Sata; Nobukazu Ishizaka; Ryozo Nagai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-25       Impact factor: 8.311

9.  Essential role of angiotensin II type 1a receptors in the host vascular wall, but not the bone marrow, in the pathogenesis of angiotensin II-induced atherosclerosis.

Authors:  Jun-ichiro Koga; Kensuke Egashira; Tetsuya Matoba; Mitsuki Kubo; Yoshiko Ihara; Masaru Iwai; Masatsugu Horiuchi; Kenji Sunagawa
Journal:  Hypertens Res       Date:  2008-09       Impact factor: 3.872

10.  The conversion of angiotensin I to angiotensin II in vivo.

Authors:  K K Ng; J R Vane
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1968
View more
  12 in total

1.  Urinary Renin in Patients and Mice With Diabetic Kidney Disease.

Authors:  Jeannette Tang; Jan Wysocki; Minghao Ye; Patricia G Vallés; Johannes Rein; Mina Shirazi; Michael Bader; Roberto Ariel Gomez; Maria-Luisa S Sequeira-Lopez; Maryam Afkarian; Daniel Batlle
Journal:  Hypertension       Date:  2019-05-13       Impact factor: 10.190

2.  Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension.

Authors:  Carlos M Ferrario; Jessica L VonCannon; Jie Zhang; Jorge P Figueroa; Kendra N Wright; Leanne Groban; Amit Saha; J Wayne Meredith; Sarfaraz Ahmad
Journal:  Peptides       Date:  2021-12-18       Impact factor: 3.750

3.  Deletion of AT1a (Angiotensin II Type 1a) Receptor or Inhibition of Angiotensinogen Synthesis Attenuates Thoracic Aortopathies in Fibrillin1C1041G/+ Mice.

Authors:  Jeff Z Chen; Hisashi Sawada; Dien Ye; Yuriko Katsumata; Masayoshi Kukida; Satoko Ohno-Urabe; Jessica J Moorleghen; Michael K Franklin; Deborah A Howatt; Mary B Sheppard; Adam E Mullick; Hong S Lu; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-08-19       Impact factor: 10.514

Review 4.  Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting.

Authors:  Hui Lin; Frank Geurts; Luise Hassler; Daniel Batlle; Katrina M Mirabito Colafella; Kate M Denton; Jia L Zhuo; Xiao C Li; Nirupama Ramkumar; Masahiro Koizumi; Taiji Matsusaka; Akira Nishiyama; Martin J Hoogduijn; Ewout J Hoorn; A H Jan Danser
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 5.  Aortic Aneurysms and Dissections Series: Part II: Dynamic Signaling Responses in Aortic Aneurysms and Dissections.

Authors:  Ying H Shen; Scott A LeMaire; Nancy R Webb; Lisa A Cassis; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-03-25       Impact factor: 8.311

Review 6.  The evolving complexity of the collecting duct renin-angiotensin system in hypertension.

Authors:  Minolfa C Prieto; Alexis A Gonzalez; Bruna Visniauskas; L Gabriel Navar
Journal:  Nat Rev Nephrol       Date:  2021-04-06       Impact factor: 28.314

Review 7.  Antisense oligonucleotides targeting angiotensinogen: insights from animal studies.

Authors:  Chia-Hua Wu; Ya Wang; Murong Ma; Adam E Mullick; Rosanne M Crooke; Mark J Graham; Alan Daugherty; Hong S Lu
Journal:  Biosci Rep       Date:  2019-01-11       Impact factor: 3.976

Review 8.  Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.

Authors:  Lauren B Arendse; A H Jan Danser; Marko Poglitsch; Rhian M Touyz; John C Burnett; Catherine Llorens-Cortes; Mario R Ehlers; Edward D Sturrock
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 9.  Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.

Authors:  Soraya Puglisi; Alessandro Rossini; Roberta Poli; Francesca Dughera; Anna Pia; Massimo Terzolo; Giuseppe Reimondo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-21       Impact factor: 5.555

10.  Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies.

Authors:  Erin S Morgan; Yvonne Tami; Kuolung Hu; Michela Brambatti; Adam E Mullick; Richard S Geary; George L Bakris; Sotirios Tsimikas
Journal:  JACC Basic Transl Sci       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.